Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Intrinsic Value Is Potentially 50% Above Its Share Price
In this article we are going to estimate the intrinsic value of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by taking the expected future cash flows and discounting them to their present value.
The FDA just approved a new painkiller. Is it too good to be true?
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
Campaignme.com on MSN22h
Predictions 2025: The year ahead for privacy and personalisation
Google’s Najeeb Jarrar says that brands that prioritise mindful marketing and champion data privacy will be the ones that ...
Vertex Q4 revenue beats Street, guidance in line with consensus
Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...
Top Vertex exec to retire after more than 12 years with company
Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.
Evercore ISI Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...